# enGene Therapeutics Inc.: Form 8-K/A, filed Jun 18, 2026

- Company: [enGene Therapeutics Inc.](/companies/engn.md) (CIK 1980845)
- Form: 8-K/A
- Filed: 2026-06-18
- Accepted by EDGAR: Jun 18, 2026, 16:06 ET
- Period: 2026-06-16
- Accession: 0001193125-26-275815
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526275815/engn-20260616.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1980845/000119312526275815/

## Items reported

- Item 2.05: Exit or disposal costs
- Item 5.02: Departure or appointment of officers or directors

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1980845/000119312526275815/engn-20260616.htm

Filed Jun 18, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-275815. Last ingested by Listed: Nov 14, 2026, 22:37 ET. No prices; not investment advice.
